Solventum Corporation $SOLV Position Lessened by Hsbc Holdings PLC

Hsbc Holdings PLC lowered its position in Solventum Corporation (NYSE:SOLV) by 4.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 248,947 shares of the company’s stock after selling 11,278 shares during the quarter. Hsbc Holdings PLC owned approximately 0.14% of Solventum worth $18,868,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. XTX Topco Ltd lifted its holdings in shares of Solventum by 26.8% during the 1st quarter. XTX Topco Ltd now owns 6,417 shares of the company’s stock valued at $488,000 after buying an additional 1,356 shares during the last quarter. Natixis Advisors LLC raised its position in Solventum by 5.1% during the first quarter. Natixis Advisors LLC now owns 57,172 shares of the company’s stock valued at $4,347,000 after acquiring an additional 2,766 shares in the last quarter. Costello Asset Management INC acquired a new stake in Solventum in the first quarter valued at approximately $42,000. Nicholas Hoffman & Company LLC. grew its position in Solventum by 25.4% in the first quarter. Nicholas Hoffman & Company LLC. now owns 8,292 shares of the company’s stock worth $631,000 after acquiring an additional 1,678 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Solventum by 2.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,173,960 shares of the company’s stock worth $89,268,000 after acquiring an additional 24,762 shares in the last quarter.

Solventum Price Performance

NYSE SOLV opened at $85.61 on Wednesday. The stock has a 50-day simple moving average of $74.25 and a 200 day simple moving average of $73.83. Solventum Corporation has a twelve month low of $60.70 and a twelve month high of $88.20. The stock has a market capitalization of $14.85 billion, a PE ratio of 9.86, a P/E/G ratio of 9.03 and a beta of 0.26. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.14 and a current ratio of 1.50.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Thursday, November 6th. The company reported $1.50 EPS for the quarter, topping the consensus estimate of $1.43 by $0.07. Solventum had a return on equity of 28.01% and a net margin of 18.13%.The company had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.05 billion. During the same period in the previous year, the business posted $1.64 EPS. The company’s revenue for the quarter was up .7% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. Research analysts anticipate that Solventum Corporation will post 6.58 EPS for the current year.

Solventum announced that its Board of Directors has authorized a share repurchase plan on Thursday, November 20th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the company to purchase up to 7.5% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board of directors believes its shares are undervalued.

Analyst Ratings Changes

Several research firms recently issued reports on SOLV. Wells Fargo & Company lifted their price objective on shares of Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a research note on Monday, September 15th. Wall Street Zen lowered Solventum from a “buy” rating to a “hold” rating in a report on Monday. BTIG Research upgraded Solventum from a “neutral” rating to a “buy” rating and set a $100.00 price target for the company in a research note on Tuesday. Jefferies Financial Group started coverage on Solventum in a report on Thursday, September 11th. They set a “hold” rating and a $80.00 price objective on the stock. Finally, UBS Group restated a “neutral” rating on shares of Solventum in a report on Friday, November 21st. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $87.00.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.